Cadrenal Therapeutics (NASDAQ:CVKD) CEO Quang Pham Sells 3,613 Shares

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) CEO Quang Pham sold 3,613 shares of the firm’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $3.18, for a total value of $11,489.34. Following the sale, the chief executive officer owned 129,102 shares in the company, valued at approximately $410,544.36. The trade was a 2.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Cadrenal Therapeutics Stock Performance

Cadrenal Therapeutics stock opened at $3.50 on Friday. The firm has a market capitalization of $10.04 million, a PE ratio of -0.62 and a beta of 1.59. Cadrenal Therapeutics, Inc. has a one year low of $3.02 and a one year high of $14.64. The stock’s 50 day moving average price is $4.93 and its 200 day moving average price is $6.46.

Cadrenal Therapeutics (NASDAQ:CVKD) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.51) by $0.47. On average, analysts forecast that Cadrenal Therapeutics, Inc. will post -5.52 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cadrenal Therapeutics

A number of institutional investors have recently made changes to their positions in the business. DRW Securities LLC acquired a new stake in shares of Cadrenal Therapeutics during the fourth quarter worth approximately $171,000. Citadel Advisors LLC bought a new stake in shares of Cadrenal Therapeutics in the third quarter worth $274,000. Geode Capital Management LLC raised its holdings in Cadrenal Therapeutics by 14.3% in the fourth quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock valued at $98,000 after acquiring an additional 1,818 shares in the last quarter. Finally, JPMorgan Chase & Co. acquired a new stake in Cadrenal Therapeutics in the third quarter valued at $103,000. 7.92% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on CVKD shares. Wall Street Zen raised shares of Cadrenal Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 9th. Weiss Ratings reissued a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research report on Monday, April 20th. Finally, HC Wainwright lowered their target price on Cadrenal Therapeutics from $32.00 to $13.00 and set a “buy” rating for the company in a research note on Tuesday, April 7th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Cadrenal Therapeutics presently has an average rating of “Hold” and an average price target of $13.00.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.